|
| | Publication Year | Title | Author(s) |
| 1 | 2-May-2022 | Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. | Weickhardt, Andrew J ; Lau, David K ; Hodgson-Garms, Margeaux; Lavis, Austen; Jenkins, Laura J; Vukelic, Natalia; Ioannidis, Paul; Luk, Ian Y; Mariadason, John M |
| 2 | 2022 | Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials. | Ledenko, Matthew; Antwi, Samuel O; Arima, Shiho; Driscoll, Julia; Furuse, Junji; Klümpen, Heinz-Josef; Larsen, Finn Ole; Lau, David K ; Maderer, Annett; Markussen, Alice; Moehler, Markus; Nooijen, Lynn E; Shaib, Walid L; Tebbutt, Niall C ; André, Thierry; Ueno, Makoto; Woodford, Rachel; Yoo, Changhoon; Zalupski, Mark M; Patel, Tushar |
| 3 | 22-Feb-2021 | Rapid resistance of FGFR-driven gastric cancers to regorafenib and targeted FGFR inhibitors can be overcome by parallel inhibition of MEK. | Lau, David K ; Luk, Ian Y; Jenkins, Laura J; Martin, Andrew; Williams, David S ; Schoffer, Kael L; Chionh, Fiona; Buchert, Michael; Sjoquist, Katrin; Boussioutas, Alex; Hayes, Sarah A; Ernst, Matthias ; Weickhardt, Andrew J ; Pavlakis, Nick; Tebbutt, Niall C ; Mariadason, John M |
| 4 | Apr-2020 | Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO Congress 2019. | Lau, David K ; Burge, Matthew; Roy, Amitesh; Chau, Ian; Haller, Daniel G; Shapiro, Jeremy D; Peeters, Marc; Pavlakis, Nick; Karapetis, Christos S; Tebbutt, Niall C ; Segelov, Eva; Price, Timothy J |
| 5 | 22-Nov-2019 | Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets. | Lau, David K ; Mouradov, Dmitri; Wasenang, Wiphawan; Luk, Ian Y; Scott, Cameron M; Williams, David S ; Yeung, Yvonne H ; Limpaiboon, Temduang; Iatropoulos, George F ; Jenkins, Laura J; Reehorst, Camilla M; Chionh, Fiona; Nikfarjam, Mehrdad ; Croagh, Daniel; Dhillon, Amardeep S; Weickhardt, Andrew J ; Muramatsu, Toshihide; Saito, Yoshimasa; Tebbutt, Niall C ; Sieber, Oliver M; Mariadason, John M |
| 6 | Apr-2018 | Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. | Lau, David K ; Tay, Rebecca Y; Yeung, Yvonne H ; Chionh, Fiona; Mooi, Jennifer; Murone, Carmel ; Skrinos, Effie; Price, Timothy J; Mariadason, John M ; Tebbutt, Niall C |
| 7 | Sep-2017 | K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. | Yeung, Yvonne; Lau, David K ; Chionh, Fiona; Tran, Hoanh; Tse, Janson W T; Weickhardt, Andrew J ; Nikfarjam, Mehrdad ; Scott, Andrew M ; Tebbutt, Niall C ; Mariadason, John M |
| 8 | 10-Nov-2014 | Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. | Parakh, S ; Murphy, C; Lau, D ; Cebon, Jonathan S ; Andrews, Miles C |
| 9 | 1-Apr-2014 | A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme. | Lau, David K ; Andrews, Miles C; Turner, Natalie; Azad, Arun A; Davis, Ian D; Cebon, Jonathan S |
Loading...
2
0
20
0
false